Polaryx Wins Two 2026 US Awards, Eyes H2 2026 SOTERIA Phase 2 Launch
Polaryx Therapeutics won Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Awards in 2026. Its lead oral small-molecule candidate PLX-200 is set to enter the SOTERIA Phase 2 basket trial evaluating multiple lysosomal storage disorder indications in the second half of 2026.
1. Award Recognition
Polaryx received two prestigious 2026 awards: Best Pediatric Lysosomal Storage Disease Therapeutics – USA and Rare Neurodegenerative Disease Drug Development Excellence – USA. The awards panel evaluated companies on innovation, market impact, business performance and contributions to patient outcomes, highlighting Polaryx’s leadership in rare disease R&D.
2. Lead Program PLX-200
PLX-200 is an oral small-molecule designed to modulate multiple disease mechanisms underlying various lysosomal storage disorders. Preclinical data demonstrate its ability to address lysosomal dysfunction, neuroinflammation and neuronal loss, positioning it as Polaryx’s most advanced therapeutic candidate.
3. Upcoming SOTERIA Phase 2 Trial
The SOTERIA Phase 2 basket trial will evaluate PLX-200 across several pediatric LSD indications, assessing safety and efficacy in distinct patient cohorts. This trial is slated to launch in the second half of 2026, marking a key milestone in Polaryx’s clinical development program.